Navigation Links
Tissue Specificity for Mutation Parallels Tissue Specificity for Cancer

d and not in others? Big Blue transgenic rodents with recoverable mutation target genes make use of the well-characterized bacterial lacI gene as a mutational target gene. The lacI gene, part of the lLIZ shuttle vector, is present in approximately 40 copies per chromosome in the mouse and rat. Mutations are efficiently assessed through the recovery of the l genome (Figure 1). High molecular weight genomic DNA is isolated from any selected Big Blue transgenic rodent tissue, which can be facilitated with the RecoverEase DNA isolation kit, and the l genomes are packaged into phage particles by Transpack lambda packaging extract.** The l particles are then plated on a specially constructed E. coli host in the presence of the chromogenic compound X-gal. Phages carrying the mutated lacI gene produce blue plaques, whereas the wild-type gene yields colorless plaques.

The ratio of blue to clear plaques indicates the mutant frequency, which in most tissues varies between 2 to 6 x 10-5, although it is often lower in the rat than the mouse. Subsequent sequencing of the mutant lacI genes reveals the specific nature of the DNA change at the molecular level; when a sufficient number of mutants have been sequenced, a mutational spectrum results. Mutational spectra are extremely useful in assessing the mechanism of mutation. DNA sequencing also permits the mutant frequency to be adjusted by allowing a correction for clonal expansion in which an individual mutation is recovered multiple times because of cell division.

Tissue Specific Effects

Researchers who have designed studies to assess mutations in a range of tis
'"/>

Source:


Page: All 1 2 3 4 5 6 7

Related biology technology :

1. Innovative Tissue Array Technology for High-Throughput Screening of Gene Expression
2. Detecting Gastrin-Releasing Peptide Receptor by in situ PCR on Archived Tissue
3. Simple Isolation of RNA from Tissue and Cultured Cells
4. Hands-free Tissue Disruption No Homogenization Needed
5. Recover High Yields of Total Nucleic Acid from Formalin-fixed, Paraffin-embedded (FFPE) Tissue
6. RNase Activity in Mouse Tissue: Classification, Hierarchy, and Methods for Control
7. Stabilizing RNA in Fresh and Frozen Tissues for RNA Isolation
8. Genomic DNA Preparation from RNAlater Preserved Tissues
9. DNA Isolation From 300 to 450 mg Dried or 600 to 1,200 mg Fresh Leaf Tissue
10. DNA Isolation From 50 to 20 mg of Paraffin-Embedded Tissue
11. Genomic DNA Isolation From 510 mg Marine Invertebrate Tissue

Post Your Comments:
(Date:12/2/2009)... , CALGARY, Dec. 2 /PRNewswire-FirstCa... "Company") (TSX:ONC; NASDAQ: ONCY ) announced tod...d unit offering, the underwriters have exercised i...n additional 637,500 units. Each unit is comprised...chase warrant, and was sold at a price of US$3.00 ...
(Date:12/2/2009)... , JERUSALEM, Israel, December 2 /...bility study evaluating the preclinical (animal st... which combines technology from Weill,Cornell Medi...potential to,treat inherited anemias such as Coole... series of technologies to expand, ex vivo,popula...
(Date:12/2/2009)... , QUEBEC CITY, Dec. 2 /PRNewswire-FirstCall/...) (the "Company"), a global biopharmaceutical comp...ay announced that the U.S. Food and Drug Administr... the Company,s PI3K/Akt pathway inhibitor compound...psed/refractory multiple myeloma. Keryx Biopharmac...
(Date:12/1/2009)... Dr. Kerry Solomon announced ... has launched his redesigned website at www.DrKer...sulting Group. Dr. Solomon is a proven LASIK, len...n professionally recognized for his substantial co.... He is a member of Trusted LASIK Surgeons, which...
Breaking Biology Technology:Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 2Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 3Oncolytics Biotech(R) Inc. Announces Exercise of Underwriters' Over-Allotment Option 4Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 2Gamida Cell Announces Feasibility Study With Weill Cornell Medical College 3AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 2AEterna Zentaris' Anti-Cancer Compound, Perifosine (KRX-0401), Receives FDA Fast Track Designation for the Treatment of Relapsed/Refractory Multiple Myeloma 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 2Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 3Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 4Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 5Charleston LASIK and Cataract Expert Dr. Kerry Solomon Opens New Practice and Launches DrKerrySolomon.com 6
..., March 31 Sigma-Aldrich (Nasdaq: SIAL ) toda...rvices and oligonucleotides to Gene Oracle, an inn...f the agreement, Sigma-Aldrich will be the exclusi...acle, and the two Companies will engage in co-mark...eir expert gene synthesis services ( http://www....
...elix Consulting US, a division of London-based Dou...ppointment of Ann Stuchiner to the position of Vic...team of highly experienced strategic pricing, reim...sive experience across the healthcare industry, wh...firms in the pharmaceutical, biotechnology and med...
... Medical Innovations, Inc. (NYSE: IMA ), a globa... their health at home through the merger of rapid ...dividend of $3.00 per share on its Series B Conver...e dividend will be paid in shares of Series B stoc...(a) $3.00 divided by (b) 97% of the average of the...
Other Biology Technology:Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 2Sigma-Aldrich Enters Exclusive Supply Agreement With Gene Oracle to Leverage Its Unique GeneIOS Gene Synthesis Platform 3Double Helix Appoints Ann Stuchiner Vice President of US Consulting Division 2
(Date:12/2/2009)..., Scientists are reporting the first identificat...transformation that changes harmless marine bacter...r study appears in ACS, Environmental Science & T...n and colleagues note that bleaching already has d...fs, and scientists are searching for ways to slow ...
(Date:12/2/2009)... , Single-walled nanotubescylinders of carbon abo...for potential applications such as ultrastrong fib...rogen storage components for fuel cells. Thanks to...Institute of Standards and Technology (NIST) and f...the list: detection and destruction of an aggressi...
(Date:12/2/2009)... , (Dec. 2, 2009) HOBOKEN, NJ According to the ...cent of Americans diagnosed with diabetes already ... retinopathy, damage to the retina caused by leaky...eople with diabetes and is one of the most feared ... of all patients who,ve had diabetes for 10 years ...
Breaking Biology News(10 mins):Combining nanotubes and antibodies for breast cancer 'search and destroy' missions 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 2Study shows pine bark improves circulation, swelling and visual acuity in early diabetic retinopathy 3Antioxidants Pose No Melanoma Threat 54669 1Antioxidants Pose No Melanoma Threat 54669 2Antioxidants Pose No Melanoma Threat 54669 3Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 1Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 2Employee Benefits Industry Organizes to Protect Flexible Spending Accounts From Elimination or Contribution Limits 54665 3Spherix Reports Second Quarter 2009 Earnings 13596 1Spherix Reports Second Quarter 2009 Earnings 13596 2Spherix Reports Second Quarter 2009 Earnings 13596 3Spherix Reports Second Quarter 2009 Earnings 13596 4Spherix Reports Second Quarter 2009 Earnings 13596 5Spherix Reports Second Quarter 2009 Earnings 13596 6Spherix Reports Second Quarter 2009 Earnings 13596 7Spherix Reports Second Quarter 2009 Earnings 13596 8
...alo Alto, CA and New York, NY, October 30, 2008 B...therapies for autoimmune diseases, and the Juvenil...g charitable funder of type 1 diabetes research, t...ongoing Phase I/II human clinical trial of BHT-302...at causes type 1 diabetes. , BHT-3021 is an antig...
...umblebee colonies which are fast learners are also...scientists from Queen Mary, University of London a...from Queen Mary,s School of Biological and Chemica...monn Mallon from the University of Leicester teste... bumblebees from twelve colonies. , The team tes...
...fter eight years of near-zero growth in atmospheri...d to rise. , "This is not good news for future gl...-authored a paper to be published in Geophysical R...ical Union. , "Over recent years, the growth of i...CFCs, had slowed. This tended to offset the increa...
Other Biology News:Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 2Bayhill Therapeutics and the Juvenile Diabetes Research Foundation announce research collaboration 3Bee smart, bee healthy 2Global methane levels on the rise again 2
Sheep Growth Hormone from Cell Sciences
Rat Anti-Mouse Semaphorin 6B Monoclonal Antibody, Unconjugated, Clone 256537 from R&D Systems
Mouse Anti-Human ADAM10 Ectodomain Monoclonal Antibody, Unconjugated, Clone 163003 from R&D Systems
Goat Anti-Human PLUNC Polyclonal Antibody, Biotin Conjugated from R&D Systems
Biology Products: